Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200
Debt
Debt-to-Equity RatioN/A
Current Ratio2.41
Quick Ratio2.41
Price-To-Earnings
Trailing P/E Ratio-3.79
Forward P/E Ratio-3.04
P/E GrowthN/A
Sales & Book Value
Annual Sales$42.22 million
Price / Sales8.90
Cash FlowN/A
Price / CashN/A
Book Value$1.58 per share
Price / Book2.61
Profitability
EPS (Most Recent Fiscal Year)($1.09)
Net Income$-88,200,000.00
Net Margins-292.06%
Return on Equity-72.04%
Return on Assets-53.90%
Miscellaneous
Employees280
Outstanding Shares90,960,000
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?
Inovio Pharmaceuticals declared a monthly dividend on Thursday, September 21st. Shareholders of record on Friday, September 29th will be paid a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 dividend on an annualized basis and a yield of 20.05%. The ex-dividend date is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Shares of Inovio Pharmaceuticals reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.22. The biopharmaceutical company earned $1.53 million during the quarter, compared to analysts' expectations of $7.50 million. Inovio Pharmaceuticals had a negative net margin of 292.06% and a negative return on equity of 72.04%. During the same period in the previous year, the business earned ($0.31) EPS. View Inovio Pharmaceuticals' Earnings History.
What price target have analysts set for INO?
5 Wall Street analysts have issued 12-month price targets for Inovio Pharmaceuticals' stock. Their predictions range from $8.00 to $14.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $11.80 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.
What are Wall Street analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Inovio announced the initiation of a P2 study of DNA-based immunotherapy VGX-3100 for HPV-related (Human Papillomavirus) anal or perianal high-grade squamous intraepithelial lesions (HSIL). This is the third in-house" HPV- related study for VGX-3100; P3 in cervical dysplasia and P2 in high-grade vulvar lesions are both ongoing. In addition, partner MedImmune (AZN – NR) is developing MEDI0457 (VGX-3100 + IL-12 ) for H&N cancer." (5/21/2018)
- 2. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year." (1/9/2018)
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Tandem Diabetes Care (TNDM), Orthofix International (OFIX), Atrion (ATRI), Intersect ENT (XENT), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Cryolife (CRY), AtriCure (ATRC), K2M Group (KTWO), Tactile Systems Technology (TCMD), Cerus (CERS) and AngioDynamics (ANGO).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Dr. J. Joseph Kim, CEO, Pres & Director (Age 49)
- Mr. Peter D. Kies, Chief Financial Officer (Age 55)
- Dr. Niranjan Y. Sardesai, Chief Operating Officer (Age 50)
- Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 57)
- Dr. Laurent M. Humeau Ph.D., Sr. VP of R&D
Has Inovio Pharmaceuticals been receiving favorable news coverage?
News stories about INO stock have trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of 0.17 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 44.64 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Inovio Pharmaceuticals' major shareholders?
Inovio Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.15%), Wasatch Advisors Inc. (2.83%), Northern Trust Corp (1.10%), Guggenheim Capital LLC (0.55%), UBS Group AG (0.49%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Which major investors are selling Inovio Pharmaceuticals stock?
INO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wasatch Advisors Inc., Barclays PLC and Northern Trust Corp. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.
Which major investors are buying Inovio Pharmaceuticals stock?
INO stock was purchased by a variety of institutional investors in the last quarter, including Guggenheim Capital LLC, UBS Group AG, Schwab Charles Investment Management Inc., New York State Common Retirement Fund and Swiss National Bank. View Insider Buying and Selling for Inovio Pharmaceuticals.
How do I buy shares of Inovio Pharmaceuticals?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of INO stock can currently be purchased for approximately $4.13.
How big of a company is Inovio Pharmaceuticals?
Inovio Pharmaceuticals has a market capitalization of $385.68 million and generates $42.22 million in revenue each year. The biopharmaceutical company earns $-88,200,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Inovio Pharmaceuticals employs 280 workers across the globe.
How can I contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]
MarketBeat Community Rating for Inovio Pharmaceuticals (INO)
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
